Latest News and Press Releases

60 Degrees Pharma begins enrolling patients for a tafenoquine babesiosis trial at Yale, Tufts, and Rhode Island Hospital, with results expected Sept., 2025

60 Degrees Pharmaceuticals enrolls first patient in a clinical study at Tufts to assess safety and efficacy of tafenoquine in treating acute babesiosis.

60 Degrees Pharmaceuticals to start the first clinical trial of tafenoquine for babesiosis at Tufts Medical Center. Enrollment begins June 13, 2024.

SAN FRANCISCO, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Videra Surgical Inc., the developer of the novel adaptable tumor bed marker VeraForm® for breast cancer surgery, announced the presentation of an...

More accurate kidney function test needed for chronic kidney disease“Silent killer” can go undetected without symptoms until patient has lost 90 percent of kidney function RESEARCH TRIANGLE PARK,...